Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Lymphangioleiomyomatosis × 90 days × Clear all

Phase

Phase 1/2 2 Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 159 Neoplasm Metastasis 128 Leukemia, Myeloid, Acute 127 Neoplasms 119 Breast Neoplasms 113 Colorectal Neoplasms 110 Ovarian Neoplasms 84 Recurrence 80 Melanoma 73 Lung Neoplasms 72 Multiple Myeloma 70 Prostatic Neoplasms 69 Squamous Cell Carcinoma of Head and Neck 66 Pancreatic Neoplasms 57 Lymphoma, Non-Hodgkin 56 Glioblastoma 56 Triple Negative Breast Neoplasms 54 Endometrial Neoplasms 54 Glioma 52 Myelodysplastic Syndromes 47 Stomach Neoplasms 44 Brain Neoplasms 44 Carcinoma, Hepatocellular 42 Carcinoma, Renal Cell 41 Lymphoma, B-Cell 39 Precursor Cell Lymphoblastic Leukemia-Lymphoma 37 Lymphoma, Large B-Cell, Diffuse 37 Lymphoma 37 Urinary Bladder Neoplasms 35 Sarcoma 34

Interventions

Imatinib Mesylate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06889168 2026-01-21

LAMP-2

Columbia University

Phase 1 Recruiting

Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡